用新辅助免疫疗法治疗恶性周周层层层层瘤,作为通往手术干预的桥梁:一个病例报告
Sohayb Faleh1,2,3, Tanya Odisho3, Florence Lebel-Guay1
1Division of General Surgical Oncology, Department of Surgery, Maisonneuve-Rosemont Hospital, Université de Montréal, Montréal, Quebec, Canada.
The American journal of case reports
|November 9, 2025
概括
恶性腹膜间皮瘤 (MPM) 是罕见的. 周围手术免疫疗法 (nivolumab-ipilimumab) 对边界/不可切除的MPM显示出希望,使得成功的细胞减小手术和高热性腹膜内化学疗法 (HIPEC) 成为可能.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 医学瘤学 医学瘤学
背景情况:
- 恶性腹膜间皮瘤 (MPM) 是一种罕见的癌症,预后不佳.
- 可切除的MPM的标准治疗包括细胞减小手术 (CRS) 和高热性腹腔内化疗 (HIPEC).
- 不能切除的MPM的治疗指南有限,但免疫疗法显示出潜力.
研究的目的:
- 报告一个边缘性/不可切除的MPM病例,用外科期免疫疗法治疗.
- 评估nivolumab-ipilimumab作为CRS和HIPEC的桥梁的疗效.
- 为了解免疫治疗在MPM管理中的作用做出贡献.
主要方法:
- 一名63岁的妇女被诊断出边界/无法切除的MPM.
- 在外科手术期间使用nivolumab-ipilimumab进行治疗.
- 随后的细胞还原性手术 (CRS) 和高热性腹腔内化疗 (HIPEC).
主要成果:
- 患者获得了术后免疫治疗的积极临床反应.
- 免疫疗法促进了成功的CRS和HIPEC.
- 患者在手术后的30个月内仍然没有疾病.
结论:
- 术后免疫疗法可能对侵略性或边缘性/不可切除的MPM有益.
- 免疫疗法可以成为巩固性CRS和HIPEC的桥梁.
- 这个案例支持进一步调查MPM的外科手术期免疫疗法.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


